Immunome (NASDAQ:IMNM) just reported results for the second quarter of 2024.
- Immunome reported earnings per share of -60 cents. This was below the analyst estimate for EPS of -39 cents.
- The company reported revenue of $2.36 million.
- This was 7.29% worse than the analyst estimate for revenue of $2.55 million.